Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent plasma and Nanogam plus for SARS-CoV-2 antibody prophylaxis in B-cell depleted adults
NL-OMON51004Completed
- Sponsor
- Erasmus MC
- Start
- May 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of Nanogam Plus and convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Erasmus MC. Primary endpoints: Duration and titer of neutralizing antibodies after convalescent plasma and Duration and titer of neutralizing antibodies after Nanogam plus. Started May 2021; status: completed.
02
Drugs
Nanogam Plusconvalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51004.